Risks and benefits : new concepts of treatment of late-onset hypogonadism
Late-onset hypogonadism (LOH) is a clinical and bio-chemical syndrome associated with advancing age in males and seriously affects the quality of life of some of the patients. A classical therapeutic option for LOH is testosterone supplementary treatment (TST). Its effectiveness has been verified, whereas its long-term safety remains to be further evaluated. With deeper insights into LOH, many new therapeutic strategies have been proposed, which include the treatments with gonadotropins, testosterone precursors (such as dehydroepiandrosterone [DHEA]), non-aromatizable androgens (such as dihydrotestosterone [DHT]), antiestrogens (such as aromatase inhibitors and estrogen receptor antagonists), and Chinese medicine. Meanwhile, studies on the transplantation of Leydig stem cells, selective androgen receptor modulators (SARMs), and selective estrogen receptor beta (ERbeta) agonists have shed new light on the treatment of LOH.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Zhonghua nan ke xue = National journal of andrology - 20(2014), 6 vom: 19. Juni, Seite 483-9 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Shang, Xue-Jun [VerfasserIn] |
|---|
| Themen: |
3XMK78S47O |
|---|
| Anmerkungen: |
Date Completed 22.01.2015 Date Revised 17.07.2014 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM240118715 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM240118715 | ||
| 003 | DE-627 | ||
| 005 | 20231224121428.0 | ||
| 007 | tu | ||
| 008 | 231224s2014 xx ||||| 00| ||chi c | ||
| 028 | 5 | 2 | |a pubmed24n0800.xml |
| 035 | |a (DE-627)NLM240118715 | ||
| 035 | |a (NLM)25029850 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Shang, Xue-Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risks and benefits |b new concepts of treatment of late-onset hypogonadism |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2015 | ||
| 500 | |a Date Revised 17.07.2014 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Late-onset hypogonadism (LOH) is a clinical and bio-chemical syndrome associated with advancing age in males and seriously affects the quality of life of some of the patients. A classical therapeutic option for LOH is testosterone supplementary treatment (TST). Its effectiveness has been verified, whereas its long-term safety remains to be further evaluated. With deeper insights into LOH, many new therapeutic strategies have been proposed, which include the treatments with gonadotropins, testosterone precursors (such as dehydroepiandrosterone [DHEA]), non-aromatizable androgens (such as dihydrotestosterone [DHT]), antiestrogens (such as aromatase inhibitors and estrogen receptor antagonists), and Chinese medicine. Meanwhile, studies on the transplantation of Leydig stem cells, selective androgen receptor modulators (SARMs), and selective estrogen receptor beta (ERbeta) agonists have shed new light on the treatment of LOH | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Testosterone |2 NLM | |
| 650 | 7 | |a 3XMK78S47O |2 NLM | |
| 700 | 1 | |a Huang, Yu-Feng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua nan ke xue = National journal of andrology |d 2002 |g 20(2014), 6 vom: 19. Juni, Seite 483-9 |w (DE-627)NLM122631390 |x 1009-3591 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2014 |g number:6 |g day:19 |g month:06 |g pages:483-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2014 |e 6 |b 19 |c 06 |h 483-9 | ||